Death Rate Significantly Higher for Trasylol

Robert Binstock

Attorney
(866) 735-1102 Ext 345

0 CommentsPrint ArticleSubscribe

According to a long awaited study published today, Bayer’s Trasylol has a 53 percent higher death rate than other similar drugs. Trasylol was withdrawn from the market in November after the drug was linked to kidney problems and other serious adverse reactions including death. Trasylol is used to reduce bleeding during heart surgery. Some experts believe that Trasylol could be responsible for as many as 22,000 preventable deaths.

The BART study, published in the New England Journal of Medicinehad to be halted after preliminary results showed an increased risk of death associated with Trasylol. The trial compared Trasylol with two different less expensive drugs on 2,331 patients. The patients were randomly assigned to one of the three drugs. Overwhelming concern from preliminary results associated with Trasylol forced researchers to halt the study. It was not until the study was published in this month’s NEJM that the true results were made public.

A commentary accompanying the study, released online by the New England Journal of Medicine, said the drug was unlikely to be returned to the market.